COQ7 defect causes prenatal onset of mitochondrial CoQ10 deficiency with cardiomyopathy and gastrointestinal obstruction
-
Published:2024-05-03
Issue:8
Volume:32
Page:938-946
-
ISSN:1018-4813
-
Container-title:European Journal of Human Genetics
-
language:en
-
Short-container-title:Eur J Hum Genet
Author:
Pettenuzzo Ilaria, Carli SaraORCID, Sánchez-Cuesta Ana, Isidori Federica, Montanari Francesca, Grippa Mina, Lanzoni Giulia, Ambrosetti Irene, Di Pisa Veronica, Cordelli Duccio Maria, Mondardini Maria CristinaORCID, Pippucci TommasoORCID, Ragni Luca, Cenacchi Giovanna, Costa RobertaORCID, Lima Mario, Capristo Maria Antonietta, Tropeano Concetta Valentina, Caporali Leonardo, Carelli Valerio, Brunelli Elena, Maffei Monica, Ahmed Sheikhmaye Hodman, Fetta AnnaORCID, Brea-Calvo GloriaORCID, Garone CaterinaORCID
Abstract
AbstractCOQ7 pathogenetic variants cause primary CoQ10 deficiency and a clinical phenotype of encephalopathy, peripheral neuropathy, or multisystemic disorder. Early diagnosis is essential for promptly starting CoQ10 supplementation. Here, we report novel compound heterozygous variants in the COQ7 gene responsible for a prenatal onset (20 weeks of gestation) of hypertrophic cardiomyopathy and intestinal dysmotility in a Bangladesh consanguineous family with two affected siblings. The main clinical findings were dysmorphisms, recurrent intestinal occlusions that required ileostomy, left ventricular non-compaction cardiomyopathy, ascending aorta dilation, arterial hypertension, renal dysfunction, diffuse skin desquamation, axial hypotonia, neurodevelopmental delay, and growth retardation. Exome sequencing revealed compound heterozygous rare variants in the COQ7 gene, c.613_617delGCCGGinsCAT (p.Ala205HisfsTer48) and c.403A>G (p.Met135Val). In silico analysis and functional in vitro studies confirmed the pathogenicity of the variants responsible for abolished activities of complexes I + III and II + III in muscle homogenate, severe decrease of CoQ10 levels, and reduced basal and maximal respiration in patients’ fibroblasts. The first proband deceased at 14 months of age, whereas supplementation with a high dose of CoQ10 (30 mg/kg/day) since the first days of life modified the clinical course in the second child, showing a recovery of milestones acquirement at the last follow-up (18 months of age). Our study expands the clinical spectrum of primary CoQ10 deficiency due to COQ7 gene defects and highlights the essential role of multidisciplinary and combined approaches for a timely diagnosis.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271:195–204. 2. Banerjee R, Purhonen J, Kallijarvi J. The mitochondrial coenzyme Q junction and complex III: biochemistry and pathophysiology. FEBS J. 2022;289:6936–58. 3. Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688–92. 4. Berardo A, Quinzii CM. Redefining infantile-onset multisystem phenotypes of coenzyme Q(10)-deficiency in the next-generation sequencing era. J Transl Genet Genom. 2020;4:22–35. 5. Salviati L, Trevisson E, Agosto C, Doimo M, Navas P. Primary Coenzyme Q (10) Deficiency Overview. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews((R)). Seattle; WA: 1993.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Summer reading in EJHG;European Journal of Human Genetics;2024-07-31 2. Primary CoQ10 deficiency: treatable heterogeneous group of disorders;European Journal of Human Genetics;2024-07-03
|
|